Multiple cardiovascular and inflammation-related targets

The term 'Multiple cardiovascular and inflammation-related targets' refers to a broad therapeutic category rather than a single, specific biological molecule. This classification encompasses a wide variety of proteins involved in the pathophysiology of heart disease and systemic inflammatory responses, such as HMG-CoA reductase, angiotensin receptors, and pro-inflammatory cytokines like IL-1β and TNF-α (Libby, 2021, Nature Reviews Cardiology). These targets are central to the 'inflammatory hypothesis of atherosclerosis,' which suggests that reducing inflammation can lower cardiovascular risk independently of lipid-lowering effects. This hypothesis was notably supported by the CANTOS trial, which targeted IL-1β to reduce major adverse cardiovascular events (Ridker et al., 2017, N Engl J Med). Other targets in this group include the NLRP3 inflammasome and various adhesion molecules that facilitate leukocyte recruitment to the vascular wall. Because this entry aggregates numerous distinct molecular entities with different structures and functions, it does not meet the criteria for a single canonical target. Consequently, it is flagged as incorrect for structured data purposes due to being overly broad and lacking molecular specificity.

Not applicable as this refers to a broad category of targets rather than a single molecular entity.